Gilead Non Current Assets Total vs Cash Analysis

GILD Stock

USD 90.49 0.30 0.33%

Gilead Sciences financial indicator trend analysis is much more than just examining Gilead Sciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gilead Sciences is a good investment. Please check the relationship between Gilead Sciences Non Current Assets Total and its Cash accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

Non Current Assets Total vs Cash

Non Current Assets Total vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gilead Sciences Non Current Assets Total account and Cash. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Gilead Sciences' Non Current Assets Total and Cash is -0.02. Overlapping area represents the amount of variation of Non Current Assets Total that can explain the historical movement of Cash in the same time period over historical financial statements of Gilead Sciences, assuming nothing else is changed. The correlation between historical values of Gilead Sciences' Non Current Assets Total and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Non Current Assets Total of Gilead Sciences are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Non Current Assets Total i.e., Gilead Sciences' Non Current Assets Total and Cash go up and down completely randomly.

Correlation Coefficient

-0.02

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Non Current Assets Total

The total value of a company's long-term assets, which are not expected to be converted into cash or used up within one year or the operating cycle, including property, plant, and equipment, and intangible assets.

Cash

Cash refers to the most liquid asset of Gilead Sciences, which is listed under current asset account on Gilead Sciences balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Gilead Sciences customers. The amounts must be unrestricted with restricted cash listed in a different Gilead Sciences account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Gilead Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.30, whereas Issuance Of Capital Stock is forecasted to decline to about 295.9 M.

	2021	2022	2023	2024 (projected)
Total Revenue	27.3B	27.3B	27.1B	28.5B
Interest Expense	1.0B	935M	944M	534.5M

Total Revenue Interest Expense

Gilead Sciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Property Plant And Equipment Gross	Short Term Investments	Inventory	Other Liab	Other Assets
Total Assets		0.96	0.91	0.98	0.95	0.91	0.7	0.93	-0.05	0.4	0.83	0.25	0.51	0.18	0.98	-0.12	0.11	0.99	0.61	0.8	0.73	0.8	0.47	0.44	0.56	0.53
Short Long Term Debt Total	0.96		0.87	0.9	0.86	0.83	0.73	0.89	-0.08	0.42	0.74	0.16	0.59	0.07	0.98	-0.04	-0.03	0.98	0.67	0.82	0.7	0.71	0.52	0.32	0.49	0.55
Other Current Liab	0.91	0.87		0.92	0.87	0.71	0.58	0.91	0.04	0.32	0.65	0.0	0.63	0.21	0.87	-0.24	-0.08	0.9	0.71	0.61	0.72	0.61	0.5	0.3	0.47	0.5
Total Current Liabilities	0.98	0.9	0.92		0.96	0.9	0.66	0.91	0.0	0.32	0.85	0.24	0.43	0.25	0.93	-0.19	0.2	0.96	0.54	0.74	0.73	0.82	0.39	0.49	0.55	0.45
Total Stockholder Equity	0.95	0.86	0.87	0.96		0.88	0.54	0.95	0.03	0.44	0.78	0.2	0.48	0.34	0.87	-0.18	0.21	0.9	0.59	0.68	0.74	0.8	0.41	0.42	0.46	0.37
Property Plant And Equipment Net	0.91	0.83	0.71	0.9	0.88		0.75	0.77	-0.25	0.18	0.95	0.45	0.16	0.05	0.87	-0.07	0.4	0.89	0.26	0.78	0.57	0.96	0.23	0.52	0.62	0.35
Net Debt	0.7	0.73	0.58	0.66	0.54	0.75		0.48	-0.27	-0.17	0.75	0.36	0.14	-0.18	0.76	-0.01	0.28	0.75	0.19	0.85	0.21	0.71	0.35	0.29	0.54	0.41
Retained Earnings	0.93	0.89	0.91	0.91	0.95	0.77	0.48		-0.03	0.55	0.64	0.06	0.68	0.19	0.88	-0.27	-0.11	0.9	0.76	0.66	0.77	0.65	0.54	0.28	0.4	0.47
Accounts Payable	-0.05	-0.08	0.04	0.0	0.03	-0.25	-0.27	-0.03		0.23	-0.22	-0.43	0.19	0.82	-0.11	0.21	0.1	-0.09	0.23	-0.2	0.27	-0.31	-0.11	0.39	-0.26	0.06
Cash	0.4	0.42	0.32	0.32	0.44	0.18	-0.17	0.55	0.23		-0.02	-0.08	0.74	0.29	0.38	0.21	-0.34	0.37	0.76	0.23	0.48	0.02	0.51	-0.05	-0.03	0.28
Non Current Assets Total	0.83	0.74	0.65	0.85	0.78	0.95	0.75	0.64	-0.22	-0.02		0.52	-0.04	0.07	0.81	-0.11	0.5	0.83	0.07	0.71	0.54	0.94	0.07	0.62	0.7	0.38
Non Currrent Assets Other	0.25	0.16	0.0	0.24	0.2	0.45	0.36	0.06	-0.43	-0.08	0.52		-0.3	-0.09	0.26	0.12	0.53	0.26	-0.29	0.47	-0.12	0.45	0.22	0.18	0.42	0.05
Cash And Short Term Investments	0.51	0.59	0.63	0.43	0.48	0.16	0.14	0.68	0.19	0.74	-0.04	-0.3		0.14	0.52	-0.05	-0.59	0.51	0.98	0.4	0.43	-0.02	0.8	-0.21	-0.05	0.39
Common Stock Shares Outstanding	0.18	0.07	0.21	0.25	0.34	0.05	-0.18	0.19	0.82	0.29	0.07	-0.09	0.14		0.06	0.2	0.4	0.1	0.2	-0.08	0.35	0.02	-0.06	0.39	-0.09	0.0
Non Current Liabilities Total	0.98	0.98	0.87	0.93	0.87	0.87	0.76	0.88	-0.11	0.38	0.81	0.26	0.52	0.06		-0.06	0.03	1.0	0.61	0.84	0.69	0.75	0.5	0.4	0.59	0.61
Other Current Assets	-0.12	-0.04	-0.24	-0.19	-0.18	-0.07	-0.01	-0.27	0.21	0.21	-0.11	0.12	-0.05	0.2	-0.06		0.28	-0.09	-0.05	-0.09	-0.12	-0.04	-0.08	0.04	0.02	-0.05
Other Stockholder Equity	0.11	-0.03	-0.08	0.2	0.21	0.4	0.28	-0.11	0.1	-0.34	0.5	0.53	-0.59	0.4	0.03	0.28		0.07	-0.53	0.17	-0.1	0.53	-0.37	0.46	0.25	-0.28
Total Liab	0.99	0.98	0.9	0.96	0.9	0.89	0.75	0.9	-0.09	0.37	0.83	0.26	0.51	0.1	1.0	-0.09	0.07		0.6	0.83	0.71	0.77	0.49	0.43	0.58	0.58
Total Current Assets	0.61	0.67	0.71	0.54	0.59	0.26	0.19	0.76	0.23	0.76	0.07	-0.29	0.98	0.2	0.61	-0.05	-0.53	0.6		0.43	0.58	0.08	0.75	-0.06	0.02	0.44
Short Term Debt	0.8	0.82	0.61	0.74	0.68	0.78	0.85	0.66	-0.2	0.23	0.71	0.47	0.4	-0.08	0.84	-0.09	0.17	0.83	0.43		0.32	0.65	0.63	0.24	0.39	0.4
Net Receivables	0.73	0.7	0.72	0.73	0.74	0.57	0.21	0.77	0.27	0.48	0.54	-0.12	0.43	0.35	0.69	-0.12	-0.1	0.71	0.58	0.32		0.47	0.12	0.59	0.33	0.47
Property Plant And Equipment Gross	0.8	0.71	0.61	0.82	0.8	0.96	0.71	0.65	-0.31	0.02	0.94	0.45	-0.02	0.02	0.75	-0.04	0.53	0.77	0.08	0.65	0.47		0.06	0.47	0.63	0.17
Short Term Investments	0.47	0.52	0.5	0.39	0.41	0.23	0.35	0.54	-0.11	0.51	0.07	0.22	0.8	-0.06	0.5	-0.08	-0.37	0.49	0.75	0.63	0.12	0.06		-0.29	0.06	0.32
Inventory	0.44	0.32	0.3	0.49	0.42	0.52	0.29	0.28	0.39	-0.05	0.62	0.18	-0.21	0.39	0.4	0.04	0.46	0.43	-0.06	0.24	0.59	0.47	-0.29		0.44	0.41
Other Liab	0.56	0.49	0.47	0.55	0.46	0.62	0.54	0.4	-0.26	-0.03	0.7	0.42	-0.05	-0.09	0.59	0.02	0.25	0.58	0.02	0.39	0.33	0.63	0.06	0.44		0.65
Other Assets	0.53	0.55	0.5	0.45	0.37	0.35	0.41	0.47	0.06	0.28	0.38	0.05	0.39	0.0	0.61	-0.05	-0.28	0.58	0.44	0.4	0.47	0.17	0.32	0.41	0.65

Click cells to compare fundamentals

Gilead Sciences Account Relationship Matchups

Gilead Sciences fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	61.6B	68.4B	68.0B	63.2B	62.1B	65.2B
Short Long Term Debt Total	24.6B	31.4B	26.7B	25.2B	25.0B	26.2B
Other Current Liab	6.5B	7.2B	8.9B	7.1B	7.7B	8.1B
Total Current Liabilities	9.8B	11.4B	11.6B	11.2B	11.3B	11.8B
Total Stockholder Equity	22.7B	18.2B	21.1B	21.2B	22.8B	24.0B
Property Plant And Equipment Net	4.5B	5.0B	5.1B	5.5B	5.3B	5.6B
Net Debt	13.0B	25.4B	21.4B	19.8B	18.9B	19.8B
Retained Earnings	19.4B	14.4B	16.3B	15.7B	16.3B	17.1B
Accounts Payable	713M	844M	705M	905M	550M	518.2M
Cash	11.6B	6.0B	5.3B	5.4B	6.1B	3.8B
Non Current Assets Total	30.1B	52.6B	52.9B	47.9B	46.0B	48.3B
Non Currrent Assets Other	7.7B	6.4B	6.0B	4.0B	4.8B	5.0B
Cash And Short Term Investments	25.8B	7.9B	7.8B	7.6B	7.3B	7.5B
Common Stock Shares Outstanding	1.3B	1.3B	1.3B	1.3B	1.3B	1.5B
Liabilities And Stockholders Equity	61.6B	68.4B	68.0B	63.2B	62.1B	65.2B
Non Current Liabilities Total	29.2B	38.8B	35.3B	30.7B	28.1B	29.5B
Other Current Assets	1.4B	2.0B	2.1B	1.8B	2.4B	1.3B
Other Stockholder Equity	3.2B	3.9B	4.7B	5.6B	6.5B	6.8B
Total Liab	39.0B	50.2B	46.9B	42.0B	39.4B	41.3B
Total Current Assets	31.5B	15.8B	15.1B	15.2B	16.1B	10.8B
Short Term Debt	2.5B	2.8B	1.5B	2.3B	1.8B	1.9B
Net Receivables	3.6B	4.9B	4.5B	4.8B	4.7B	2.4B
Property Plant And Equipment Gross	4.5B	5.0B	7.0B	7.7B	7.8B	8.2B
Accumulated Other Comprehensive Income	85M	(60M)	83M	2M	28M	37.6M
Short Term Investments	12.7B	1.4B	1.2B	973M	1.2B	1.1B
Inventory	2.1B	3.0B	2.7B	2.8B	1.8B	1.3B
Other Liab	6.5B	9.5B	35.3B	7.3B	8.4B	8.8B
Other Assets	3.1B	4.8B	6.0B	1M	1.2M	1.1M
Long Term Debt	22.1B	28.6B	25.2B	23.0B	23.2B	12.2B
Property Plant Equipment	4.5B	5.0B	5.1B	5.5B	6.3B	6.6B
Net Tangible Assets	4.6B	(23.0B)	(20.7B)	(16.0B)	(14.4B)	(13.7B)
Noncontrolling Interest In Consolidated Entity	125M	19M	(5M)	(31M)	(84M)	(79.8M)
Retained Earnings Total Equity	19.4B	14.4B	16.3B	15.7B	18.0B	12.7B
Long Term Debt Total	22.1B	28.6B	25.2B	23.0B	26.4B	19.7B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:

How To Invest In Gilead

Details

Is Gilead Stock a good investment?

Details

What is Gilead Sciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.42)

Dividend Share

3.06

Earnings Share

0.09

Revenue Per Share

22.703

Quarterly Revenue Growth

0.07

The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Gilead Non Current Assets Total vs Cash Analysis

Non Current Assets Total vs Cash

Non Current Assets Total vs Cash Correlation Analysis

Correlation Coefficient

Non Current Assets Total

Cash

Gilead Sciences fundamental ratios Correlations

Gilead Sciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Gilead Sciences fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Non Current Liabilities Total
Total Liab	+ 0.99	Total Assets
Total Current Liabilities	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.98	Total Assets
Non Current Liabilities Total	+ 0.98	Short Long Term Debt Total
Total Liab	+ 0.98	Short Long Term Debt Total

Other Stockholder Equity	- 0.59	Cash And Short Term Investments
Total Current Assets	- 0.53	Other Stockholder Equity
Non Currrent Assets Other	- 0.43	Accounts Payable
Short Term Investments	- 0.37	Other Stockholder Equity
Other Stockholder Equity	- 0.34	Cash
Property Plant And Equipment Gross	- 0.31	Accounts Payable